The EFPC has responded to a public consultation from the European Ombudsman on how the European Medicines Agency engages with medicine developers before they apply for authorisations to market their medicines in the EU.

This public consultation is part of an inquiry conducted by the European Ombudsman and aims to elicit information, views and concerns of all stakeholder groups with interest in the EMA “pre-submission activities”.

You can find here the response from the Network of Primary Health Care to European Medicines Agency (EMA) – EFPC Working Group